Cesium

What is Cesium?

Cesium chloride is sold to consumers at 500 mg to 3 g per serving as a cancer treatment, and in the 11 of 20 published poisoning cases where a corrected QT interval was recorded, the median was 620 milliseconds. A QTc above 500 ms is the threshold at which cardiologists begin treating a patient as at risk of sudden death. That pairing, a product marketed as therapy and a measured effect that is a cardiac emergency, is what makes this issue different from anything else in the archive.

Cesium is element 55, an alkali metal sitting below rubidium and potassium in group 1 of the periodic table, with an atomic weight of 132.905. Naturally occurring cesium consists of exactly one stable isotope, cesium-133, and the element is rare in the crust: granites average about 1 part per million, sedimentary rocks about 4 ppm. Nothing sold to consumers contains the metal, which melts at 28.5 C and reacts violently with water. What is sold is a salt, almost always cesium chloride, CsCl, which is 78.9 percent cesium by mass and dissolves freely in water.

Common Names

Cesium chloride, CsCl, “high pH therapy,” “the cesium protocol,” “alkaline therapy,” cesium carbonate, cesium hydroxide. Some sellers list it simply as “cesium” on a trace mineral panel next to boron and vanadium, which puts a cardiotoxic salt in the same visual category as a nutrient.

Primary Active Compounds

The cesium cation, Cs+, is the only species that matters. The chloride, carbonate or hydroxide counter-ion changes taste, solution pH and gastrointestinal tolerability, but in every documented human case the physiological effect traces to Cs+ and what it does to potassium channels.

Key Note

Cesium is a potassium mimic with an ionic radius of 1.67 angstroms against potassium’s 1.38. That size difference lets it enter a potassium channel and lodge there without passing through. The property has made cesium a standard laboratory reagent for blocking potassium currents since at least 1976, and it is the same property that has killed people who swallowed it.

Primary Functions & Benefits

Cesium has no established function in human physiology, and this section covers what it actually does in a body rather than what it is supposed to do.

What Cs+ does on contact with excitable tissue

Cesium enters cells through the same routes potassium uses, though the systems that move potassium handle it poorly. Once inside and outside the cell in appreciable quantity, it obstructs the inward rectifier potassium channels of the KCNJ family by two mechanisms documented in the 2026 Cardiovascular Toxicology review by Brouwer and colleagues: the ion becomes trapped inside the selectivity filter and physically plugs it, and it binds at external sites that prevent potassium moving outward. It also inhibits the HCN pacemaker channels in the low millimolar range, which is the accepted explanation for the sinus bradycardia seen in 6 of the 20 reviewed cases.

What that produces clinically

Blocked repolarizing potassium current lengthens the cardiac action potential, which shows on an electrocardiogram as a prolonged QT interval. QT prolongation appeared in 14 of the 20 reviewed cases, polymorphic ventricular tachycardia in 9, and torsades de pointes specifically in 6.

The only legitimate uses

Cesium chloride has real applications, none of them therapeutic. It is a density gradient medium for ultracentrifugation, used since the 1950s to separate nucleic acids, and a reagent for blocking potassium currents in electrophysiology experiments. Cesium-based atomic clocks define the SI second as 9,192,631,770 oscillations of the cesium-133 hyperfine transition. None of these implies anything about swallowing the salt.

Forms & Standardization

This section covers the toxicology of each chemical form rather than a comparison of bioavailability, because there is no desirable effect to be more or less available.

Cesium chloride (CsCl)

The dominant retail and compounded form, and the one in 16 of the 18 poisoning cases where the salt was identified. Molecular weight 168.36, of which 132.905 is cesium, so 1.5 g of CsCl delivers roughly 1.18 g of Cs+, or about 8.9 millimoles. It is deliquescent, highly water soluble and readily absorbed from the gut, which is why the salt form does almost nothing to blunt the exposure. Public Citizen’s petition of July 23, 2018 documented retail products at 1.5 g CsCl per 15 mL serving, Amazon listings at 1.5 to 3.0 g per serving, and 500 mg capsules.

Cesium carbonate (Cs2CO3)

Used in 2 of the 20 reviewed cases. Marketed on the argument that the carbonate anion adds alkalinizing capacity beyond the cesium itself. The carbonate is a stronger gastric irritant than the chloride. The cardiac risk is identical because the cardiac risk belongs to the cation.

Cesium hydroxide (CsOH)

A strong base, corrosive to tissue, appearing in some “liquid ionic cesium” preparations. Any product delivering CsOH in solution carries chemical burn risk on top of everything else.

Liquid ionic and colloidal preparations

Sold in dropper bottles with concentrations given in parts per million rather than milligrams, which makes the delivered dose difficult to compute. A solution of a few hundred parts per million delivers single-digit milligrams of cesium in a 15 mL serving, far below the doses in the poisoning literature, while a product listing 1.5 g per 15 mL is squarely in that range. Two bottles on the same shelf can differ by more than two orders of magnitude.

Standardization

There is none. Cesium chloride has no USP monograph for supplement use, no compendial identity or assay standard for oral products, and no third-party certification program. Grade designations on labels, including “99.9 percent” and “ACS reagent,” describe purity of the raw salt and say nothing about the safety of ingesting it.

Food Sources

This section covers routes of exposure rather than sources worth seeking. Background cesium exposure is unavoidable and vanishingly small, and there is no reason to increase it.

Ordinary diet and water

Stable cesium is present everywhere at low concentration. ATSDR reports background cesium-133 in fresh lakes and rivers at 0.01 to 1.2 micrograms per liter and in seawater at about 0.5. Danish onion samples averaged 0.21 micrograms per kilogram, range not detected to 0.98. Pakistani wheat flour measured 6.7 to 11.2 parts per billion, while American wheat flour showed none detectable.

What that adds up to

Typical daily intake from food and water is in the low micrograms. CDC’s NHANES biomonitoring gives geometric mean urinary cesium of 4.26 micrograms per liter in adults aged 20 and over, 4.54 in adolescents aged 12 to 19, and 4.87 in children aged 6 to 11, with males at 4.83 and females at 3.94. To reach the median dose in the poisoning literature, 23.8 millimoles of Cs+ per day, a person would need to consume roughly 3.2 grams of cesium daily. Food does not come close by a factor of hundreds of thousands. The background exposure is real and biologically irrelevant, and no dietary pattern meaningfully changes it.

The actual exposure route that matters

Mineral waters drawn from granitic aquifers run higher than surface water, and pollucite ore is the commercial source of the element, but neither is a route by which anyone accumulates a clinically relevant burden. Every serious cesium case in the medical literature involves a product someone bought and swallowed or injected, not food.

Who Should Take Cesium

No one should take cesium in any form, at any dose, for any indication. There is no population for whom the risk-benefit calculation favors it. This section covers who is exposed without choosing to be, and who has reason to be tested.

People with unavoidable background exposure

Everyone. Cesium is in soil, water and food at the concentrations given above, and nothing can or should be done about it.

People who should consider testing

Anyone who has taken a cesium salt product, or who has been treated by a practitioner using a “high pH” or “alkaline” cancer protocol, should have a 12-lead electrocardiogram with a measured QTc, a serum potassium, and a serum magnesium. Whole blood or serum cesium can be measured by inductively coupled plasma mass spectrometry through reference laboratories. The relevant point is that cesium’s biological half-life in humans runs roughly 2 to 4 months, with the Radiogardase label citing a whole-body effective half-life near 80 days in adults, so a normal electrocardiogram two weeks after stopping does not clear someone. Risk persists for months.

People treating a family member

The 2013 case reported by Sessions, Heard and Kosnett involved a 61-year-old woman with a breast mass and no formal cancer diagnosis who had taken oral cesium chloride for about a year on a nutritionist’s recommendation, then received an injection of the oral preparation around the mass, administered at home. She arrested in August 2011 and died at home less than a week after the exposure. Anyone administering a cesium product to someone else should stop and take them to an emergency department.

Who Should AVOID or Use Caution

Contraindications

Everyone, without exception. No medical condition creates an indication for cesium and no dose has been shown safe.

Groups at compounded risk

Several situations turn a dangerous exposure into an acutely lethal one.

• Anyone with congenital long QT syndrome, or a family history of unexplained sudden death or drowning. Cesium prolongs QT on top of an already prolonged baseline.

• Anyone taking a QT-prolonging drug. Amiodarone, sotalol, quinidine, dofetilide, methadone, ondansetron, fluoroquinolones, macrolides and haloperidol all add to the effect.

• Anyone taking a loop or thiazide diuretic, or a corticosteroid. Both waste potassium, and potassium depletion is one of cesium’s two routes to arrhythmia.

• Anyone with chronic kidney disease. Cesium is cleared mainly by the kidneys, so impaired clearance extends an already long half-life.

• Anyone with existing hypokalemia, hypomagnesemia, vomiting or diarrhea, anorexia, bulimia, or cancer cachexia.

• Anyone with structural heart disease, prior myocardial infarction, or bradycardia. Cesium inhibits HCN pacemaker channels and produced sinus bradycardia in 6 of 20 reviewed cases, and slow heart rates lengthen QT further.

• Pregnant and breastfeeding women, and children. Cesium crosses membranes freely and there are no safety data in either group. A pediatric case, reported by O’Brien and colleagues in Pharmacotherapy in 2008, documented cesium-induced QT prolongation in an adolescent.

Critical Safety Point

Cesium harmed people at low doses. The 2019 case published by Hetavi and colleagues in Journal of Medical Cases involved a 77-year-old woman with stage IV colon cancer taking an over-the-counter cesium supplement at 500 mg daily. Her potassium was 3.5 mEq/L, magnesium 1.5 mg/dL, heart rate 42, QT interval 662 to 735 ms. She presented with a witnessed cardiac arrest and CPR, then had polymorphic ventricular tachycardia treated with lidocaine, isoproterenol and a transvenous pacemaker before a permanent dual-chamber device was implanted. That was 500 mg a day of a product legally listed for sale.

Recommended Dosages

There is no recommended dosage of cesium. No amount is endorsed by any health authority, and every number below is either a regulatory boundary or a dose that harmed someone. None of them is an amount to consume.

Regulatory position

FDA’s Center for Drug Evaluation and Research concluded in a May 31, 2016 reviewer assessment, carried into the Pharmacy Compounding Advisory Committee briefing document of June 23, 2016, that cesium chloride is not safe for human use and has not been shown effective for preventing or treating any form of cancer. In July 2018 FDA placed cesium chloride in the category of bulk drug substances presenting significant safety risks, removing it from the enforcement policy that had allowed 503A compounding. On February 5, 2020 FDA issued a public health alert telling consumers to avoid dietary supplements containing cesium chloride or any other cesium salt. On October 9, 2020 it sent warning letters to five firms, including American Nutriceuticals LLC, Daily Manufacturing Inc. and Essence-of-Life LLC, on the basis that the products were adulterated because cesium chloride is a new dietary ingredient that never satisfied the conditions for lawful marketing. There is no tolerable upper intake level, because setting one would imply a safe range.

Doses documented in poisoning cases

Across the 11 of the 20 cases reviewed in 2026 with a documented dose, median intake was 23.8 millimoles of Cs+ per day, interquartile range 17.8 to 53.5, corresponding to roughly 4 g of cesium chloride daily at the median and about 9 g at the upper quartile. Harm occurred at far less: the Hetavi case was 500 mg daily. Sartori’s 1984 report described patients given up to 30 g per day.

Doses promoted by sellers

The Public Citizen petition documented a clinic protocol running from 1.5 g twice daily up to 15 g daily. Products on sale delivered 1.5 to 3.0 g per serving, and 500 mg per capsule.

Duration

Harm has been documented after a single injection and after a year of daily use. One self-experimenter, reported by Neulieb in 1984, developed loss of appetite, nausea and diarrhea over 36 days.

Timing & Administration

There is no correct way to take cesium, so this section covers what administration practices appear in the case literature and why each one raised the risk.

Oral

The predominant route in the reviewed cases. Cesium salts are absorbed nearly completely from the gastrointestinal tract, so taking the dose with food, splitting it, or buffering it changes the peak but not the total exposure. Sellers commonly instruct users to take it with meals to reduce nausea, which does not reduce absorption.

Intravenous and intratumoral

Used alone or with oral dosing in a minority of reviewed cases, typically in a clinic. IV delivery bypasses the only natural brake in the system, which is that gastrointestinal upset limits how much a person can keep down. The Sessions 2013 fatality involved injection of an oral cesium chloride preparation around a breast mass, which puts a bolus of a potassium channel blocker into the circulation.

The instruction that makes it worse

Cesium protocols routinely tell users to take potassium supplements alongside, on the theory that this offsets the potassium loss. It does not reliably do so, and it can create false reassurance: the user believes the problem is being managed while renal potassium wasting continues. In the reviewed cases, hypokalemia was present in 10 of the 12 patients whose potassium was recorded, with a median of 3.05 millimoles per liter and an interquartile range of 2.8 to 3.25.

If someone is taking it now

Stop, and seek medical assessment the same day rather than tapering. There is no withdrawal syndrome and no reason to continue any dose.

Timeline of Effects

This section maps when harm appears, since there is no beneficial effect to time.

Hours to days

Gastrointestinal effects come first: nausea, loss of appetite, diarrhea. Perioral and peripheral tingling, numbness of the lips, hands and feet, and light-headedness are reported early. Sartori claimed pain relief within 1 to 3 days and Brewer claimed that all cancer pain and effects disappeared within 12 to 36 hours, claims that no independent investigator has ever reproduced and that formed part of the basis for the 2026 removal of both papers.

Days to weeks

Potassium depletion develops over this window, driven by renal wasting, impaired dietary uptake and diarrheal losses together. QT prolongation follows the falling potassium and the direct channel block. Syncope is frequently the first symptom that brings a patient in, and by then the QTc is often already beyond 600 ms. The Neulieb self-experiment ran 36 days, with symptoms documented throughout.

Weeks to months

This is where cardiac arrest and death cluster. In the 2026 review, cardiac arrest occurred in 7 of 20 patients and 5 died, a case fatality of 25 percent. Causes of death were 2 cardiac arrests, 1 unspecified arrhythmia, 1 seizure with sepsis, and 1 undocumented.

After stopping

Cesium leaves slowly. Whole-body effective half-life is roughly 80 days in adults without treatment, and total clearance takes months. Cases have required temporary pacing, isoproterenol infusions, lidocaine, magnesium and potassium repletion, and in 3 reviewed cases Prussian blue, sustained over days to weeks while the ion cleared.

What counts as a fair trial

Nothing. There is no efficacy endpoint to wait for, which is the point of the section.

Benefits of Taking Cesium

There are no benefits. No controlled trial has shown cesium to treat, shrink or slow any cancer, and none has shown benefit for any other condition. This section covers the history of the claim as history.

The theory and where it came from

A. Keith Brewer, a physicist who had worked on mass spectrometry, proposed that raising the intracellular pH of tumor cells with an alkali metal would halt mitosis, and that cesium would do it best. He published “The high pH therapy for cancer tests on mice and humans” in Pharmacology Biochemistry and Behavior in 1984, in a supplement drawn from the 2nd Annual Toxicology Conference held in El Paso, Texas in October 1983. Hellfried Sartori published “Cesium therapy in cancer patients” in the same supplement. Brewer died in 1986.

Why the theory was backwards

The pH biology of tumors is now well characterized and it runs the opposite way to Brewer’s premise. Cancer cells maintain an intracellular pH above 7.2, against roughly 7.2 in normal cells, while the tumor’s extracellular pH is acidic at about 6.7 to 7.1 against 7.4 in normal tissue. Alkaline intracellular pH is what supports cancer cell proliferation, increased glycolysis and adaptation to hypoxia, and acidifying the interior is what compromises tumor growth. Brewer’s proposal was to push intracellular pH in the direction tumors already push it themselves.

What the original reports contained

Brewer reported tumor disappearance in over 30 patients, with all cancer pain and effects resolving within 12 to 36 hours. Sartori reported 50 patients with advanced disease and a claimed 50 percent recovery rate, though roughly half of those terminal patients were alive at one year and a quarter died within the first two weeks. Neither report carried control groups or long-term follow-up, and neither has been independently verified in the 42 years since.

How it ended

Marcel van der Heyden of University Medical Center Utrecht reported his concerns to the journal in July 2025 after his group encountered the papers while compiling a review of cesium case reports. Elsevier removed both articles in May 2026, stating it had attempted to contact the authors without success. The notice reads that the article was removed at the request of the editor-in-chief due to serious concerns regarding the reliability of the findings reported. Brewer’s paper had been cited 45 times and Sartori’s 39.

Potential Negatives & Side Effects

Gastrointestinal

Nausea, vomiting, loss of appetite and diarrhea are the most common early effects and appear across the case literature, including the 36-day self-experiment reported by Neulieb in 1984. The diarrhea is not incidental. It contributes directly to the potassium losses that drive the cardiac risk.

Neurological

Perioral numbness, tingling of the lips, hands and feet, and paresthesias. Seizures appeared in 2 of the 16 patients catalogued in the 2018 Public Citizen petition, and one of the 5 deaths in the 2026 review was a seizure with sepsis. Khangure and colleagues documented elevated cesium concentrations in brain tissue in 2013.

Cardiovascular

The dominant category. QT prolongation in 14 of 20 reviewed cases, with a median QTc of 620 ms and an interquartile range of 596 to 691 ms among the 11 with a recorded value. Polymorphic ventricular tachycardia in 9, torsades de pointes specifically in 6, sinus bradycardia in 6, cardiac arrest in 7. Syncope is common and is often the presenting complaint. Hypotension is reported.

Metabolic

Hypokalemia in 10 of 12 patients with recorded values, median 3.05 mmol/L. Hypomagnesemia frequently accompanies it and independently worsens QT prolongation.

Who it happened to

The 20 reviewed patients were 14 female and 6 male, nearly half aged 40 to 49, predominantly from the United States and Canada, and 15 of the 20 were using cesium as an alternative cancer treatment. These were not people misusing an industrial chemical. They were patients following instructions.

Deficiency Symptoms

There is no such thing as cesium deficiency. The element has no biochemical role in humans, no transport protein specific to it, no enzyme that requires it, and no deficiency state has ever been produced in any animal model. A substance with no physiological job cannot be in short supply.

What a real trace element deficiency looks like, for contrast

Selenium is genuinely essential and the contrast is instructive. Selenium deficiency causes Keshan disease, an endemic cardiomyopathy in low-selenium regions of China, and it is reversible with supplementation. A systematic review and meta-analysis in Biological Trace Element Research pooled 41 studies from 17 articles covering 1,983,238 subjects, 683,075 supplemented and 1,300,163 controls, and found a risk ratio of 0.14 with a 95 percent confidence interval of 0.12 to 0.16, an 86 percent reduction. Protection exceeded 80 percent in 35 of the 41 studies.

That is the evidentiary shape of a real essential element: a defined deficiency disease with a geographic distribution, a measurable biomarker, a dose-response, and a supplementation trial that eliminates it in hundreds of thousands of people. Cesium has none of those things, at any level of evidence.

What cesium addresses

Nothing. No symptom, syndrome or laboratory abnormality is caused by low cesium or corrected by giving it.

Bottom line

Low blood cesium on a laboratory panel is a normal finding with no clinical meaning. If a practitioner presents a low cesium value as a problem requiring correction, that finding is being manufactured, and the correction offered is the hazard.

Toxicity Symptoms

At any measurable supplemental intake

Cesium is unusual in that the toxic dose and the marketed dose overlap completely. The lowest intake associated with a documented cardiac arrest in the published literature is 500 mg per day of an over-the-counter cesium supplement, a single capsule of a product that was legally on sale.

Early

Loss of appetite, nausea, diarrhea, numbness and tingling of the lips, hands and feet, light-headedness and hypotension.

Established

Syncope, palpitations, bradycardia, prolonged QT interval on electrocardiogram, hypokalemia, hypomagnesemia, seizures.

Severe

Torsades de pointes, polymorphic ventricular tachycardia, ventricular fibrillation, cardiac arrest, death. Five deaths among 20 published cases is a 25 percent case fatality among those sick enough to be written up.

What to do about an exposure

Any person who has taken cesium and develops fainting, palpitations, seizure or chest discomfort needs an emergency department, not a phone call. Treatment documented across the case series includes stopping the cesium, intravenous magnesium and potassium repletion, lidocaine, isoproterenol, overdrive pacing, electrical cardioversion, CPR, and Prussian blue. Insoluble Prussian blue, marketed as Radiogardase and approved by FDA in October 2003 in 0.5 g capsules, binds cesium in the gut by ion exchange and interrupts its enterohepatic recycling. Prussian blue cut the mean whole-body effective half-life of cesium in adults by 69 percent, from about 80 days to about 25.

General note

Recovery is slow because elimination is slow. Several patients required weeks of monitored care and permanent pacemaker implantation.

How Cesium Works

Cesium works by impersonating potassium badly enough to break the machinery that handles potassium.

The chemistry

Cs+ carries the same single positive charge as K+ and sits in the same periodic table group, so cellular systems that recognize potassium by charge and by hydration energy partially accept cesium. The sizes differ: potassium’s ionic radius is 1.38 angstroms, rubidium’s 1.52, cesium’s 1.67. A potassium channel selectivity filter is tuned to strip potassium’s hydration shell and pass the bare ion. Cesium enters, is too large to pass cleanly, and becomes trapped.

At the channel

The 2026 review describes two distinct blocking mechanisms for inward rectifier channels of the KCNJ family. In the first, the cesium ion lodges within the selectivity filter and physically obstructs potassium passage. In the second, cesium binds at sites outside the filter and prevents outward potassium movement. Cesium also blocks HCN pacemaker channels at low millimolar concentrations, slowing the sinus node. Because it blocks the repolarizing currents, the cardiac action potential lengthens and the QT interval on the surface electrocardiogram stretches.

At the kidney and the gut

Potassium channels are not only cardiac. Blocking them in the renal tubule causes potassium wasting into the urine, while gut channel blockade impairs dietary potassium uptake and the resulting diarrhea adds further losses. Serum potassium falls.

The second hit

Hypokalemia is itself one of the most reliable causes of QT prolongation and torsades de pointes in clinical medicine, entirely independent of cesium. So the same molecule delivers the arrhythmia twice: directly by blocking the channel, and indirectly by depleting the ion the channel carries. Add the bradycardia from HCN blockade, which lengthens QT further at slow rates, and three routes converge on one failure mode. That is why a median QTc of 620 ms across a case series is not a marginal signal.

Synergistic Supplements

Nothing is synergistic with cesium, because there is no effect worth potentiating. This section covers what gets sold alongside it and why those combinations raise the danger.

Potassium

Routinely recommended within cesium protocols to offset losses. Supplementing potassium does not neutralize channel blockade and does not reliably prevent hypokalemia, since the loss is driven by continuous renal wasting. What it provides is a reason to keep taking the cesium.

Magnesium

Genuinely useful, but as an antidote rather than a partner. Intravenous magnesium sulfate is a standard treatment for torsades de pointes. Its appearance in cesium regimens reflects that the people designing them knew arrhythmia was on the table.

“Alkalizing” stacks

Sodium bicarbonate, cesium carbonate, alkaline water and pH drops are bundled with cesium under the same high pH premise. Bicarbonate loading carries its own risk of metabolic alkalosis, which shifts potassium into cells and lowers serum potassium further.

The honest version of this section

High-dose intravenous vitamin C and DMSO appear in the same clinic protocols alongside cesium infusions, and neither modifies its cardiac toxicity. The only thing worth adding is a 12-lead electrocardiogram and a basic metabolic panel.

Interactions & What NOT to Take

QT-prolonging drugs

The most dangerous class. Amiodarone, sotalol, dofetilide, quinidine, procainamide, methadone, ondansetron, haloperidol, citalopram and escitalopram, fluoroquinolone antibiotics such as levofloxacin and moxifloxacin, macrolides such as azithromycin and clarithromycin, and several antifungals all prolong QT. Their effect is additive with cesium’s, on a baseline that cesium has already stretched past 600 ms in the published cases.

Potassium-wasting drugs

Loop diuretics such as furosemide, thiazides such as hydrochlorothiazide, and corticosteroids including prednisone and dexamethasone all lower serum potassium. Layering any of them onto cesium accelerates the arrhythmia mechanism. Many cancer patients are on dexamethasone as an antiemetic, which places exactly the wrong population in exactly the wrong combination.

Drugs that cause vomiting or diarrhea

Most cytotoxic chemotherapy, and laxatives. Both deepen potassium losses.

Digoxin

Digoxin toxicity is potentiated by hypokalemia, and digoxin inhibits the sodium-potassium ATPase that cesium already interferes with.

Insulin and beta-agonists

Insulin and albuterol drive potassium into cells and lower serum potassium acutely. A cesium user given a nebulizer treatment for asthma has just been pushed closer to the arrhythmia threshold.

Laboratory interference

Cesium is detected by ICP-MS panels but is not on most standard toxicology screens, so a patient presenting with unexplained torsades de pointes will not have cesium found unless someone asks for it. Cesium exposure typically comes to light only when a clinician asks what supplements the patient is taking.

Quality, Testing & Adulteration

The identity problem is not the usual one

In most issues this section asks whether the product contains what the label claims. With cesium the problem is the reverse: products that do contain what they say, in quantities that cause cardiac arrest. Verifying the contents does not make the contents safe.

Legal status of the ingredient

FDA’s position in the October 9, 2020 warning letters was that cesium chloride is a new dietary ingredient for which no firm has ever satisfied the notification requirements under the Dietary Supplement Health and Education Act of 1994, so products containing it are adulterated. Steven Tave, then director of FDA’s Office of Dietary Supplement Programs, said the agency would keep acting against such products because of heart toxicity and potential death. That is not a labeling dispute. The ingredient has no lawful basis for sale in a supplement at all.

Dose disclosure and testing

Labeling ranges from milligram amounts per capsule to parts per million in a dropper bottle to “proprietary mineral blend” with no quantity given. The Public Citizen petition documented products at 1.5 g per 15 mL, 1.5 to 3.0 g per serving, and 500 mg capsules, a sixfold span among disclosed products alone. USP, NSF and ConsumerLab certify none of them, and a supplier’s certificate of analysis reports elemental purity of the salt, which is a specification for a laboratory chemical.

Enforcement history

Allen J. Hoffman of T-Up Inc. in Baltimore was sentenced in 2001 to 46 months in federal prison, one year of supervised release and $222,506 in restitution on two felony counts of introducing an unapproved new drug into interstate commerce with intent to defraud, after treating more than 3,000 patients. FDA’s 2018 compounding action and 2020 warning letters followed. Products remained findable online after each step.

What a buyer can verify

That the ingredient is not lawfully sold in a supplement, and that FDA has told consumers to avoid it. Both are checkable in minutes and settle the question.

Special Considerations

Cesium-137 is a different subject and must not be confused with this one

Cesium-137 is a radioactive fission product with a physical half-life of about 30 years. Stable cesium-133 is the only isotope found in nature. Sellers occasionally exploit the confusion in both directions, either reassuring buyers that their product “is not the radioactive kind,” which is true and irrelevant, or borrowing the seriousness of radiological medicine to imply clinical legitimacy. The distinction is real: cesium-137 harms by ionizing radiation, cesium-133 harms by blocking potassium channels. Neither fact excuses the other.

The Goiânia accident of September 1987 shows how thoroughly the topics differ while sharing a chemical formula. A teletherapy source was scavenged from an abandoned clinic in Goiás, Brazil, and its cesium-137 chloride, a soluble blue-glowing powder, was handled and passed through the community. About 250 people were contaminated, four died within the first month, and cleanup produced roughly 3,500 cubic meters of radioactive waste. That salt was chemically the same compound sold in supplement bottles. What killed people there was the isotope. What has killed people in the supplement cases is the chemistry.

Cancer patients specifically

Fifteen of the 20 patients in the 2026 review were using cesium as an alternative cancer treatment. This is a population often on QT-prolonging antiemetics, on corticosteroids, with electrolyte losses from chemotherapy, and with a reason to try something unproven. Every one of those factors multiplies the cesium risk.

Reporting

Adverse events involving supplements can be reported to FDA MedWatch at 1-800-FDA-1088. Sparse reporting to FDA’s CAERS database was among the reasons the agency gave in February 2020 for declining to ban the ingredient outright, so reports have practical consequences.

Research Status & Evidence Quality

Evidence for benefit: none, at any tier

There are no randomized controlled trials of cesium chloride in cancer or in any other condition. There are no controlled cohort studies. There is no registered trial with published results. The entire affirmative evidence base consisted of two 1984 papers by Brewer and Sartori in a single conference supplement of Pharmacology Biochemistry and Behavior, both without control groups, robust data or follow-up, and both removed by Elsevier in May 2026. Preclinical work has not rescued the idea: Low and colleagues assessed cesium chloride in prostate cancer xenografts in nude mice in 2007, found reduced growth in one of the two tumor lines, and reported acute toxicities alongside it.

Evidence for harm: consistent case-report evidence spanning four decades

The 2026 review by Brouwer and colleagues in Cardiovascular Toxicology, published January 5, 2026, pooled 20 cases from 19 reports. Individual reports include Neulieb 1984, Lyon and Mayhew 2003, Dalal, Harding and Verdino 2004 on acquired long QT and monomorphic ventricular tachycardia after cesium chloride for brain cancer, O’Brien and colleagues 2008 in an adolescent, Chan and colleagues 2009 on life-threatening torsades de pointes, Wiens and colleagues 2009, Sessions, Heard and Kosnett 2013 on a fatality, Horn and colleagues 2015 on cesium-associated hypokalemia treated with amiloride, and Hetavi and colleagues 2019.

Research Limitations

Case reports cannot establish incidence, and nobody knows the denominator. How many people have taken cesium chloride without being written up is unmeasured, so the 25 percent case fatality describes published cases, not users. Only one case report has appeared since the 2018 FDA action, which the review’s authors read as declining use rather than declining harm.

The meta-point about the literature itself

Two papers with no supporting data sat in a peer-reviewed Elsevier journal for 42 years, accumulated 84 citations between them, and were used to market a cardiotoxic salt to cancer patients the entire time. The review’s authors asked the journal for an editorial note on the whole 1984 supplement. That is a clear illustration of how long a bad paper can do commercial work after the science has moved on.

Summary & Key Takeaways

Cesium chloride is the rare case where the marketing claim and the documented effect point in opposite directions, and the documented effect is the lethal one.

• Do not take it. No dose, no form, no indication. FDA barred cesium chloride from 503A compounding in July 2018, alerted consumers on February 5, 2020, and issued warning letters to five firms on October 9, 2020 on the basis that cesium chloride is an unlawful ingredient in a supplement.

• The theory is backwards. Brewer’s 1984 premise was that raising tumor intracellular pH kills cancer. Tumor cells already maintain an intracellular pH above 7.2 against roughly 7.2 in normal cells, and that alkalinity is what supports their proliferation.

• The founding papers no longer exist. Elsevier removed both 1984 articles in May 2026 over the reliability of the findings, 42 years and 84 citations later.

• The numbers that matter are cardiac. Across 20 published cases: QT prolongation in 14, median QTc 620 ms among the 11 with a recorded value, polymorphic ventricular tachycardia in 9, torsades de pointes in 6, cardiac arrest in 7, five deaths.

• Low doses are not safe doses. A documented cardiac arrest followed 500 mg per day of an over-the-counter product in a 77-year-old woman with a QT interval measured at 662 to 735 ms.

• The mechanism is potassium. Cesium’s ionic radius of 1.67 angstroms against potassium’s 1.38 lets it jam potassium channels, and blocking the same channels in kidney and gut drives hypokalemia, which prolongs QT again. Hypokalemia appeared in 10 of 12 patients with recorded values, median 3.05 mmol/L.

• Cesium-137 is a separate topic. Radioactive cesium-137, half-life about 30 years, harms through ionizing radiation. Stable cesium-133, the only natural isotope, harms through channel blockade. The 1987 Goiânia accident involved the same chemical salt and roughly 250 contaminated people, and has no bearing on the supplement question.

• Background intake is irrelevant. Adult geometric mean urinary cesium is 4.26 micrograms per liter and drinking water runs 0.01 to 1.2 micrograms per liter, against a median poisoning dose of about 3.2 grams of cesium daily. Food is not the exposure of concern. Purchase is.

• If you or someone you know has taken it, get a 12-lead electrocardiogram with a measured QTc, a serum potassium and a serum magnesium. Cesium’s whole-body half-life is near 80 days, so risk persists for months after the last dose.